Sterling Drug
American pharmaceutical company
Sterling Drug was an American based global pharmaceutical company. It was also known as Sterling Winthrop, Inc., after the merger with Winthrop-Stearns Inc. which itself resulted from the merger of Winthrop Chemical Company Inc. and Frederick Stearns & Company. It was formerly known as Sterling Winthrop Pharmaceuticals.
Primary product lines included diagnostic imaging agents, hormonal products, cardiovascular products, analgesics, antihistamines and muscle relaxants.
Chemical compounds produced by this company were often known by their manufacturing code which consisted of the abbreviation WIN (for Winthrop) followed by a number. For example, WIN 18,320 was nalidixic acid, the first quinolone antibiotic.
History
1910s
The Company was established in 1901 (then called Neuralgyline Co.) in Wheeling, West Virginia, by Albert H. Diebold and William E. Weiss, a pharmacist. At the end of World War I in 1918, Sterling purchased the US assets of a German company now known as Bayer AG for US$5.3 million.
Begin with the source’s own compact description: “Sterling Drug” is american pharmaceutical company. The dossier treats that line as a proposition to test through Sterling, Drug and American, not as a finished interpretation.
Why this record matters
The phrase “american pharmaceutical company” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Contemporary correspondence, administrative files and participant testimony can test how later narratives organized the event or institution. The source revision retrieved here is dated Sep 19, 2026. The linked authority identifier is Q7611398. VIAF identifies the subject as 151334758. The Library of Congress control number is n85134602. 2 of 3 selected statements include explicit references; 0 carry qualifiers and 0 use preferred rank. The first chronological checks are 1901 and 1918.
Official terminology may obscure informal participation, dissent or communities documented only indirectly. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Compare institutional narratives with records created by participants and affected communities. Dates and formal titles are useful anchors, but not substitutes for context.
- Event chronology
- Institutional context
- Locating named record creators
Contemporary correspondence, government or organizational records, oral histories and cited historical scholarship.
Three-step research path
- Establish the record: confirm the title “Sterling Drug”, its source revision and the description used here.
- Expand the search: follow Sterling Drug primary sources, Sterling Drug archive and Sterling research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Sterling Drug”?
- Who created the surviving record, and for what administrative purpose?
- Which voices are present, absent or mediated by the institution?
Search terms from this dossier
This entry incorporates text from “Sterling Drug” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.